SAPCD1
gene geneOn this page
Also known as NG23
Summary
SAPCD1 (suppressor APC domain containing 1, HGNC:13938) is a protein-coding gene on chromosome 6p21.33, encoding Suppressor APC domain-containing protein 1 (Q5SSQ6).
At a glance
- GWAS associations: 27
- MANE Select transcript:
NM_001039651
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:13938 |
| Approved symbol | SAPCD1 |
| Name | suppressor APC domain containing 1 |
| Location | 6p21.33 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | NG23 |
| Ensembl gene | ENSG00000228727 |
| Ensembl biotype | protein_coding |
| Entrez | 401251 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron
ENST00000415669, ENST00000425424, ENST00000494299, ENST00000927045
RefSeq mRNA: 1 — MANE Select: NM_001039651
NM_001039651
CCDS: CCDS34411
Canonical transcript exons
ENST00000415669 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003585238 | 31764266 | 31764355 |
| ENSE00003778000 | 31763415 | 31763555 |
| ENSE00003790115 | 31764064 | 31764159 |
| ENSE00003978189 | 31764436 | 31764850 |
| ENSE00003978190 | 31762656 | 31763168 |
Expression profiles
Bgee: expression breadth ubiquitous, 133 present calls, max score 90.31.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0512 / max 20.3556, expressed in 17 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 67042 | 0.0512 | 17 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| skin of leg | UBERON:0001511 | 90.31 | gold quality |
| right uterine tube | UBERON:0001302 | 89.88 | gold quality |
| zone of skin | UBERON:0000014 | 88.05 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 85.19 | gold quality |
| skin of abdomen | UBERON:0001416 | 85.17 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.61 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 82.81 | gold quality |
| metanephros cortex | UBERON:0010533 | 82.72 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 82.41 | gold quality |
| spleen | UBERON:0002106 | 81.64 | gold quality |
| granulocyte | CL:0000094 | 80.94 | gold quality |
| cortex of kidney | UBERON:0001225 | 80.84 | gold quality |
| pituitary gland | UBERON:0000007 | 80.43 | gold quality |
| right testis | UBERON:0004534 | 80.12 | gold quality |
| adenohypophysis | UBERON:0002196 | 79.80 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 79.54 | gold quality |
| ventricular zone | UBERON:0003053 | 79.12 | gold quality |
| tibial nerve | UBERON:0001323 | 78.91 | gold quality |
| transverse colon | UBERON:0001157 | 78.81 | gold quality |
| left testis | UBERON:0004533 | 78.75 | gold quality |
| prostate gland | UBERON:0002367 | 78.71 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 78.68 | gold quality |
| testis | UBERON:0000473 | 78.08 | gold quality |
| right ovary | UBERON:0002118 | 76.84 | gold quality |
| small intestine | UBERON:0002108 | 76.68 | gold quality |
| left ovary | UBERON:0002119 | 76.59 | gold quality |
| body of uterus | UBERON:0009853 | 76.59 | gold quality |
| right lobe of liver | UBERON:0001114 | 76.37 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 76.31 | gold quality |
| ovary | UBERON:0000992 | 75.99 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.58 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
26 targeting SAPCD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-95-5P | 99.89 | 72.17 | 3973 |
| HSA-MIR-129-5P | 99.88 | 70.26 | 3273 |
| HSA-MIR-3680-3P | 99.75 | 72.51 | 3095 |
| HSA-MIR-5004-5P | 99.68 | 66.63 | 1294 |
| HSA-MIR-3175 | 99.65 | 66.30 | 2031 |
| HSA-MIR-4666B | 99.64 | 68.69 | 1282 |
| HSA-MIR-4328 | 99.57 | 71.06 | 4094 |
| HSA-MIR-516B-5P | 99.56 | 66.33 | 1495 |
| HSA-MIR-6081 | 99.48 | 66.07 | 1446 |
| HSA-MIR-1224-5P | 99.48 | 65.59 | 803 |
| HSA-MIR-12131 | 99.48 | 68.72 | 1673 |
| HSA-MIR-12113 | 99.32 | 67.54 | 1072 |
| HSA-MIR-4784 | 99.15 | 67.41 | 1733 |
| HSA-MIR-4424 | 98.91 | 70.33 | 1145 |
| HSA-MIR-3150B-3P | 98.81 | 67.21 | 1728 |
| HSA-MIR-6878-5P | 98.49 | 67.91 | 2142 |
| HSA-MIR-4733-3P | 98.35 | 65.20 | 994 |
| HSA-MIR-876-5P | 97.99 | 68.49 | 1345 |
| HSA-MIR-6783-5P | 97.67 | 67.21 | 1528 |
| HSA-MIR-6824-5P | 97.41 | 68.43 | 583 |
| HSA-MIR-505-5P | 97.01 | 65.54 | 778 |
| HSA-MIR-3167 | 96.81 | 67.09 | 1236 |
| HSA-MIR-345-5P | 96.40 | 66.43 | 663 |
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Sapcd1 | ENSMUSG00000036185 |
| rattus_norvegicus | Sapcd1 | ENSRNOG00000000858 |
| drosophila_melanogaster | CG3880 | FBGN0035057 |
| caenorhabditis_elegans | WBGENE00020134 |
Paralogs (1): SAPCD2 (ENSG00000186193)
Protein
Protein identifiers
Suppressor APC domain-containing protein 1 — Q5SSQ6 (reviewed: Q5SSQ6)
Alternative names: Protein G7d
All UniProt accessions (2): Q5SSQ6, A0A1U9X8I8
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q5SSQ6-1 | 1 | yes |
| Q5SSQ6-2 | 2 |
RefSeq proteins (1): NP_001034740* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR026828 | SAPC2_1/2 | Family |
Pfam: PF11414
UniProt features (5 total): sequence variant 2, chain 1, region of interest 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q5SSQ6-F1 | 75.98 | 0.29 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 104 (showing top):
GSE45365_NK_CELL_VS_CD11B_DC_UP, BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP, BOYLAN_MULTIPLE_MYELOMA_C_D_UP, MIKKELSEN_ES_LCP_WITH_H3K4ME3, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN, FOSTER_KDM1A_TARGETS_UP, GSE5503_MLN_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_DN, GSE5503_MLN_DC_VS_SPLEEN_DC_ACTIVATED_ALLOGENIC_TCELL_DN, GSE10240_CTRL_VS_IL17_AND_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP, MIR4328, MIR6081, MIR5004_5P, MIR345_5P, MIR505_5P
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (0):
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 1 |
Protein interactions and networks
STRING
280 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SAPCD1 | VWA7 | Q9Y334 | 570 |
| SAPCD1 | PLEKHG5 | O94827 | 560 |
| SAPCD1 | OR2H1 | Q9GZK4 | 547 |
| SAPCD1 | ZNF391 | Q9UJN7 | 542 |
| SAPCD1 | PSORS1C2 | Q9UIG4 | 504 |
| SAPCD1 | P2RX5 | Q93086 | 475 |
| SAPCD1 | FKBP10 | Q96AY3 | 471 |
| SAPCD1 | C14orf93 | Q9H972 | 447 |
| SAPCD1 | ANXA3 | P12429 | 400 |
| SAPCD1 | LY6G6C | O95867 | 390 |
| SAPCD1 | FAM241A | Q8N8J7 | 373 |
| SAPCD1 | MSH5 | O43196 | 371 |
| SAPCD1 | LY6G6F | Q5SQ64 | 362 |
| SAPCD1 | OR12D2 | P58182 | 360 |
| SAPCD1 | NELFE | P18615 | 350 |
IntAct
124 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SAPCD1 | ARHGAP21 | psi-mi:“MI:0407”(direct interaction) | 0.590 |
| SAPCD1 | PATJ | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | MAGI2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | MAGI3 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | PDZD7 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | DLG1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| MAST2 | SAPCD1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| DLG4 | SAPCD1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | TAMALIN | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | GRID2IP | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | DLG2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | DLG4 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | APBA1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | SNTB1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | DLG3 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | MPDZ | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | SNTA1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| DLG1 | SAPCD1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | FRMPD2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | SHANK1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SYNJ2BP | SAPCD1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | ARHGEF12 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | NOS1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | GOPC | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | MAGI1 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| SAPCD1 | SNTG2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
BioGRID (26): CTNNA2 (Affinity Capture-MS), ARHGAP21 (Affinity Capture-MS), ARHGAP23 (Affinity Capture-MS), RANGRF (Affinity Capture-MS), CTNNB1 (Affinity Capture-MS), ARHGAP21 (Affinity Capture-MS), ARHGAP23 (Affinity Capture-MS), RANGRF (Affinity Capture-MS), CTNNA2 (Affinity Capture-MS), CTNNB1 (Affinity Capture-MS), CTNNA1 (Affinity Capture-MS), SAPCD1 (Affinity Capture-RNA), SAPCD1 (Two-hybrid), SAPCD1 (Two-hybrid), SAPCD1 (Two-hybrid)
ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0
Diamond homologs: Q5SSQ6, Q86UD0, Q9CY86, Q9D818
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 79 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Ras activation upon Ca2+ influx through NMDA receptor | 5 | 53.9× | 1e-06 |
| Unblocking of NMDA receptors, glutamate binding and activation | 5 | 51.3× | 1e-06 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 5 | 51.3× | 1e-06 |
| Assembly and cell surface presentation of NMDA receptors | 10 | 47.9× | 6e-13 |
| Dopamine Neurotransmitter Release Cycle | 5 | 46.8× | 2e-06 |
| Long-term potentiation | 5 | 44.9× | 2e-06 |
| Neurexins and neuroligins | 11 | 40.9× | 3e-13 |
| Protein-protein interactions at synapses | 7 | 35.1× | 7e-08 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| establishment or maintenance of epithelial cell apical/basal polarity | 10 | 75.5× | 2e-14 |
| protein localization to synapse | 6 | 59.7× | 9e-08 |
| receptor clustering | 7 | 56.7× | 7e-09 |
| regulation of postsynaptic membrane neurotransmitter receptor levels | 6 | 38.6× | 8e-07 |
| protein-containing complex assembly | 9 | 13.3× | 2e-06 |
| cell-cell adhesion | 10 | 13.2× | 4e-07 |
| regulation of small GTPase mediated signal transduction | 5 | 9.3× | 4e-03 |
| protein localization to plasma membrane | 6 | 8.5× | 2e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
0 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
923 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:31763165:TTGGG:T | donor_loss | 1.0000 |
| 6:31763167:GG:G | donor_gain | 1.0000 |
| 6:31763168:GG:G | donor_gain | 1.0000 |
| 6:31763169:GTGA:G | donor_loss | 1.0000 |
| 6:31764264:A:AG | acceptor_gain | 1.0000 |
| 6:31764265:G:GG | acceptor_gain | 1.0000 |
| 6:31763164:TTTGG:T | donor_gain | 0.9900 |
| 6:31763165:TTGG:T | donor_gain | 0.9900 |
| 6:31763169:G:GG | donor_gain | 0.9900 |
| 6:31763170:T:G | donor_loss | 0.9900 |
| 6:31763171:GAG:G | donor_loss | 0.9900 |
| 6:31763413:A:AG | acceptor_gain | 0.9900 |
| 6:31763414:G:GA | acceptor_gain | 0.9900 |
| 6:31763414:GC:G | acceptor_gain | 0.9900 |
| 6:31763414:GCT:G | acceptor_gain | 0.9900 |
| 6:31763414:GCTAC:G | acceptor_gain | 0.9900 |
| 6:31763513:G:GT | donor_gain | 0.9900 |
| 6:31763552:TGAGG:T | donor_loss | 0.9900 |
| 6:31763553:GAGGT:G | donor_loss | 0.9900 |
| 6:31763554:AGGTA:A | donor_loss | 0.9900 |
| 6:31763555:GGT:G | donor_loss | 0.9900 |
| 6:31763557:T:G | donor_loss | 0.9900 |
| 6:31764265:G:GA | acceptor_gain | 0.9900 |
| 6:31763166:TGG:T | donor_gain | 0.9800 |
| 6:31763167:GGG:G | donor_gain | 0.9800 |
| 6:31763172:AGTAT:A | donor_loss | 0.9800 |
| 6:31763412:CA:C | acceptor_loss | 0.9800 |
| 6:31763414:G:GG | acceptor_gain | 0.9800 |
| 6:31763414:GCTA:G | acceptor_gain | 0.9800 |
| 6:31763514:G:T | donor_gain | 0.9800 |
AlphaMissense
1146 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:31763157:T:C | F35L | 0.939 |
| 6:31763159:C:A | F35L | 0.939 |
| 6:31763159:C:G | F35L | 0.939 |
| 6:31764116:T:C | I103T | 0.930 |
| 6:31764137:T:C | L110S | 0.929 |
| 6:31763438:G:C | E46D | 0.928 |
| 6:31763438:G:T | E46D | 0.928 |
| 6:31763463:G:C | G55R | 0.906 |
| 6:31763437:A:T | E46V | 0.903 |
| 6:31763426:G:A | M42I | 0.894 |
| 6:31763426:G:C | M42I | 0.894 |
| 6:31763426:G:T | M42I | 0.894 |
| 6:31763425:T:C | M42T | 0.885 |
| 6:31763160:T:C | F36L | 0.882 |
| 6:31763162:C:A | F36L | 0.882 |
| 6:31763162:C:G | F36L | 0.882 |
| 6:31763496:T:C | F66L | 0.880 |
| 6:31763498:T:A | F66L | 0.880 |
| 6:31763498:T:G | F66L | 0.880 |
| 6:31764116:T:G | I103S | 0.861 |
| 6:31763464:G:A | G55D | 0.836 |
| 6:31763416:T:C | L39P | 0.834 |
| 6:31763473:T:C | L58P | 0.826 |
| 6:31763447:G:C | Q49H | 0.818 |
| 6:31763447:G:T | Q49H | 0.818 |
| 6:31764067:T:C | F87L | 0.816 |
| 6:31764069:T:A | F87L | 0.816 |
| 6:31764069:T:G | F87L | 0.816 |
| 6:31763448:G:C | D50H | 0.804 |
| 6:31763509:T:C | L70P | 0.804 |
dbSNP variants (sampled 300 via entrez): RS1001668923 (6:31761838 T>C), RS1003393864 (6:31763425 T>A), RS1004034887 (6:31763111 G>A,C), RS1006120529 (6:31764975 C>T), RS1006483649 (6:31763546 C>A), RS1006864594 (6:31765014 C>G,T), RS1009296444 (6:31761048 A>G), RS1010076963 (6:31760998 C>T), RS1010770999 (6:31764903 C>T), RS1011061316 (6:31762634 G>A), RS1012995215 (6:31763963 C>A,G,T), RS1013103927 (6:31761661 T>G), RS1015875466 (6:31763114 G>A,T), RS1017138945 (6:31764994 T>C), RS1017648727 (6:31761054 C>A,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
27 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST003450_2 | Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia | 3.000000e-09 |
| GCST004131_25 | Inflammatory bowel disease | 2.000000e-31 |
| GCST004133_79 | Ulcerative colitis | 5.000000e-65 |
| GCST004521_114 | Autism spectrum disorder or schizophrenia | 3.000000e-17 |
| GCST004521_117 | Autism spectrum disorder or schizophrenia | 3.000000e-15 |
| GCST004521_126 | Autism spectrum disorder or schizophrenia | 2.000000e-10 |
| GCST004521_154 | Autism spectrum disorder or schizophrenia | 3.000000e-08 |
| GCST004521_17 | Autism spectrum disorder or schizophrenia | 2.000000e-12 |
| GCST004521_209 | Autism spectrum disorder or schizophrenia | 5.000000e-16 |
| GCST004521_211 | Autism spectrum disorder or schizophrenia | 5.000000e-15 |
| GCST004521_213 | Autism spectrum disorder or schizophrenia | 5.000000e-13 |
| GCST004521_224 | Autism spectrum disorder or schizophrenia | 5.000000e-10 |
| GCST004521_227 | Autism spectrum disorder or schizophrenia | 4.000000e-12 |
| GCST004521_265 | Autism spectrum disorder or schizophrenia | 7.000000e-14 |
| GCST004521_281 | Autism spectrum disorder or schizophrenia | 5.000000e-09 |
| GCST004521_296 | Autism spectrum disorder or schizophrenia | 6.000000e-18 |
| GCST004521_45 | Autism spectrum disorder or schizophrenia | 2.000000e-16 |
| GCST004521_70 | Autism spectrum disorder or schizophrenia | 8.000000e-20 |
| GCST004521_81 | Autism spectrum disorder or schizophrenia | 1.000000e-14 |
| GCST006228_4 | Systolic blood pressure | 6.000000e-08 |
| GCST006230_2 | Pulse pressure | 3.000000e-09 |
| GCST006575_37 | Takayasu arteritis | 8.000000e-08 |
| GCST006950_12 | Feeling worry | 2.000000e-08 |
| GCST008916_111 | Asthma | 2.000000e-14 |
| GCST008916_30 | Asthma | 1.000000e-09 |
| GCST008917_2 | Asthma (childhood onset) | 4.000000e-07 |
| GCST008921_1 | Asthma and major depressive disorder | 2.000000e-16 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006335 | systolic blood pressure |
| EFO:0005763 | pulse pressure measurement |
| EFO:0009589 | worry measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
18 total (human), top 18 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | decreases expression, decreases methylation | 2 |
| Tobacco Smoke Pollution | decreases expression | 2 |
| Valproic Acid | affects expression, increases expression | 2 |
| GSK-J4 | decreases expression | 1 |
| 2,5,2’,5’-tetrachlorobiphenyl | decreases expression | 1 |
| trichostatin A | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | increases expression | 1 |
| jinfukang | increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Diethylhexyl Phthalate | decreases expression | 1 |
| Plant Oils | decreases expression | 1 |
| Smoke | decreases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 1 |
| Cyclosporine | decreases expression | 1 |
| Lactic Acid | decreases expression | 1 |
| Acrylamide | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): childhood onset asthma, Takayasu arteritis